Peter A. Lio, MD

In this video, Peter Lio, MD, highlighted research from the American Academy of Dermatology meeting and said his biggest takeaway from the meeting was that dermatologists are in “the decade of atopic dermatitis.”

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

MIAMI BEACH, Fla. — The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology.

MIAMI BEACH, Fla. — Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according to a speaker at Masters of Pediatric Dermatology.

Babies born during the lockdown of March through May 2020 developed significant differences in their microbiome and less atopic dermatitis compared with babies born prior to this period, according to a study published in Allergy.

Abrocitinib downregulated genes associated with inflammation, epidermal hyperplasia, and T helper 2 and T helper 22 responses in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.

Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The FDA has approved a supplemental new drug application to expand the use of abrocitinib for adolescents with atopic dermatitis when other systemic drug products are not adequate or advisable, according to a press release.